Twist Bioscience

Twist Bioscience completed a US$300 million follow-on equity offering at US$96/share, upsized from an initially filed US$250 million raise. Concurrent with Q3 2026 results showing US$118.38M revenue and US$35.05M loss, company raised FY2026 guidance to US$456-457M.

Leadership read: Twist Bioscience's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.

curated · 2026-08-17 · context →

Twist Bioscience priced a $300 million stock offering at $96 per share, indicating successful capital raise in public markets.

Leadership read: Twist Bioscience's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.

curated · 2026-08-05 · context →

Twist Bioscience filed an omnibus shelf registration and registered a $200M at-the-market (ATM) follow-on equity offering of common shares in June 2026.

Leadership read: Twist's ATM structure commits it to sustained equity issuance against market demand rather than a single priced round, a deliberate choice that preserves flexibility but signals the company is not yet cash-generative at the scale its platform ambitions require. The shelf registration, covering the full capital stack, adds further optionality. What this exposes operationally is that Twist is positioning its synthetic DNA infrastructure as foundational to AI genomics workflows, liquid biopsy sample prep, outsourced wet-lab capacity for model training, and needs runway to grow into that positioning before revenue catches up to the narrative. This is one of twelve capital-raising signals we tracked on the same date, a cluster that spans sectors from defense tech to cargo drones to clinical biotech. Within life sciences specifically, Nura Bio's $73.8M Series B and the broader pattern of platform-infrastructure raises point to a market consolidating around companies that supply enabling layers, synthesis, sequencing infrastructure, data inputs, rather than end therapeutics. Twist sits squarely in that enabling-layer category, and institutional attention from funds like Osterweis confirms that the AI genomics infrastructure thesis is attracting crossover capital, not just specialist biotech money. Companies at this stage of platform-infrastructure build in genomics face concentrated demand for commercial leadership capable of translating wet-lab utility into enterprise AI partnerships, alongside operations and quality leadership able to scale synthesis capacity under regulated conditions. The market is moving toward operators who can close the loop between biological data production and computational consumption.

curated · 2026-06-22 · context →